It seeks $300m valuation on junior market. According to Bloomberg, Liquidia Technologies, a biotechnology firm backed by the Bill & Melinda Gates Foundation, is planning a Singapore initial public offering this year, according to people with knowledge of the matter. The U.S. company aims to list on Singapore’s junior Catalist market at a valuation of about S$300 million ($211 million), the people said, asking not to be identified because the information is private. Liquidia is in early talks with investors including Malaysian sovereign fund Khazanah Nasional Bhd. about selling a stake before the proposed offering, according to the people.Liquidia was founded in 2004 and is led by Chief Executive Officer Neal Fowler, the former president of Johnson & Johnson’s Centocor unit. The company’s current investors include GlaxoSmithKline Plc, the largest U.K. drugmaker, as well as venture capital firms Canaan Partners, New Enterprise Associates Inc. and Morningside Group, according to its website. A listing would be a boon to Singapore Exchange Ltd.’s attempts to attract foreign listings as the city-state builds its reputation as a regional hub for biotech companies. Fundraising from Singapore IPOs surged more than fourfold last year to $1.7 billion, data compiled by Bloomberg show. “Liquidia continues to evaluate its capital needs, but does not comment on these matters publicly,” said Michael Parks, a spokesman for the North Carolina-based company. “The company’s current focus is on delivering for its partners and advancing its internal product pipeline.” A representative for Khazanah declined to comment.
Liquidia’s technology allows it to develop highly precise particle-based vaccines and therapeutics, according to its website. News by Bloomberg and Singapore Business Reviews Share by Corwin Group
0 Comments
Leave a Reply. |
CORWIN GROUPLatest News Archives
October 2021
CategoriesBy submitting this form, you provide consent for Corwin Group to email you occasionally with industry news and promotions. You may unsubscribe from these emails at any time.Testimonials & Disclaimer
Important Disclosure: By visiting this site, you agree to be bound by CorwinGroup’s Terms of Use and Privacy Policy. CorwinGroup.com is intended for accredited investors and otherwise qualified investors who understand and accept the risk associated with private investments. Investing in private investments on CorwinGroup involves risks, including, but not limited to market and industry risks, risks related to a specific property, currency fluctuation risk and liquidity constraints. Investments are not bank deposits and are not guaranteed. There is a potential for loss of part or ALL of the investment capital. CorwinGroup does not endorse any of the opportunities that appear on the site, nor does it make any recommendations regarding the appropriateness of particular opportunities for any investor. No correspondence or information provided on CorwinGroup.com or by any representative of CorwinGroup should be construed as a recommendation of a security. Each investor is advised to conduct his/her own due diligence as CorwinGroup does not provide any investment advice, business advice, or tax or legal advice. CorwinGroup is not registered under the Securities & Futures Act or the Financial Advisor’s Act. Neither the Securities and Exchange Commission in the country nor any federal or state securities commission or any other regulatory authority has recommended or approved of the investment or the accuracy or inaccuracy of any of the information or materials provided by or through the website. Please read Corwin’s Terms of Use for more detailed terms and conditions to which users of CorwinGroup are subject. |